Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study

Main Article Content

Andrew Blauvelt
Kim A Papp
Joseph F Merola
Alice B Gottlieb
Nancy Cross
Cindy Madden
Luke Peterson
Christopher Cioffi
Christopher EM Griffiths

Keywords

psoriasis, bimekizumab, scalp, nail

Abstract

Abstract not available.

References

1. Klaassen KMG et al. J Eur Acad Dermatol Venereol. 2014;28:1690-1695.

2. Sampogna F et al. Acta Derm Venereol. 2014;94:411-414.

3. Aldredge LM et al. J Dermatol Nurs Assoc. 2018;10:189-197.

4. Merola JF et al. Dermatol Ther. 2018;31(3):e12589.

5. Glatt S et al. Ann Rheum Dis. 2018;77:523-532.

6. Glatt S et al. Br J Clin Pharmacol. 2017;83:991-1001.

7. Papp KA et al. J Am Acad Dermatol. 2018;79:277-286.

8. Blauvelt A et al. AAD. 2019 [OP11180].